Top NYC, NY Social Impact Companies With Best Stability & Growth (155)

Investor Backing & Capital Strength: A ~$100M raise in July 2024 at a ~$2.3B valuation—about double the prior year—signals strong investor confidence and provides resources to scale. Leadership also cited a clear line of sight to company‑level profitability.

Strong Market Position & Advantage: A provider network approaching 50,000 versus a key rival’s ~17,000, plus 6,000,000+ hours of care and 1,000,000 patients in 2024, indicate scaled utilization and reach. Such scale supports competitive differentiation in insurance‑enabled behavioral health.

Market Expansion: Expansion into Medicare Advantage with Medicaid planned for 2025 and nationwide integrated primary‑care‑to‑mental‑health referrals broaden the addressable market. Payer expansion alongside network growth supports demand capture.

Strong Revenue Growth: Direct revenue is rising at a double‑digit pace, with recent quarters and the full year showing year‑over‑year gains. Payers and revenue per payer also increased, indicating both user monetization and scale are contributing.

Market Expansion: The app is gaining traction in new regions, leading download charts in targeted European countries and quickly reaching top‑tier ranks in Mexico and Brazil. Monthly active users in expansion markets grew significantly, reinforcing international momentum.

Future-Ready Strategy: Management positions the business as a core growth engine with continued international rollout and margin improvement. Guidance indicates ongoing momentum even as broader portfolio trends are mixed.

Strong Market Position & Advantage: Reported presence in over two‑thirds of U.S. districts and an estimated annual reach of 25 million students signal entrenched adoption in K–8 supplemental content. Ongoing district contracts and widespread classroom usage references suggest durable positioning.

Product Line Growth: Recent updates span LMS integrations via Clever, new content collections (e.g., AI Literacy), and 21 new movies in 2025 alongside continued build‑out of BrainPOP Science. This steady roadmap indicates active investment to deepen use cases and support retention.

Investor Backing & Capital Strength: KIRKBI’s 2022 acquisition and continued emphasis on BrainPOP’s “next phase of growth” provide resources and mandate to scale. Leadership appointments across 2025 were framed to accelerate innovation and district focus.

Strong Revenue Growth: Recent disclosures indicate rising revenue with improving ARPU and a larger base of paying subscribers under the parent company. This momentum suggests stronger monetization alongside user expansion.

Investor Backing & Capital Strength: Upbound completed the acquisition and characterized Brigit as accretive to EBITDA, signaling confidence and resources to invest. Placement within a public parent supports continued scaling and product development.

Future-Ready Strategy: Management outlined ongoing expansion into 2026 with expected benefits from scale and product additions within the portfolio. Guidance points to a meaningful contribution to consolidated results as offerings grow.

Market Expansion: Recent company and LinkedIn posts highlight launches or restarts of new teams in Grand Rapids and Mid‑Michigan alongside activity across multiple states, indicating selective geographic growth in 2026. The company’s site also notes it has launched in multiple states with a tech‑enabled model for high‑need SMI populations.

Investor Backing & Capital Strength: The company has secured substantial funding, including a $28.1M round led by GV in 2023 and an additional round reported in 2025, providing capital to support expansion efforts. These financings underscore continued access to growth capital during rebuilding.

Strategic Partnerships: Materials and trade press describe payer relationships across multiple states, with collaborations tied to Medicaid managed‑care contracts and references to partners such as Molina and Carelon. Such arrangements underpin a contract‑driven growth model when conditions allow.

Profitability: Results indicate improved profitability in 2025, with management emphasizing margin quality as the mix shifts toward higher‑margin offerings. Guidance and commentary describe deliberate trade‑offs to favor profitability over scale.

Product Line Growth: Pharma Manufacturer Solutions/“Pharma Direct” expanded rapidly in 2025 and was cited as a key driver of results. Management also highlighted emerging subscriptions and Employer Direct as longer‑term growth vectors.

Diversified Revenue Streams: The business is increasingly balanced between manufacturer solutions, select subscriptions, and employer offerings rather than relying solely on prescription transactions. This mix shift supports stronger unit economics even if total revenue growth is muted.

Market Expansion: Global operations across North America, EMEA, and APJ with an expanded city footprint and new institutional partnerships indicate widening geographic and channel reach. Active hiring across sales, operations, and engineering supports scaling service delivery.

Innovation-Driven Growth: A unified SaaS platform and API plus a direct buyback model differentiate the offer from traditional ITAD vendors. ISO-aligned data sanitization and software-tracked chain-of-custody target enterprise requirements and enable scalable adoption.

Resilient & Sustainable Growth: Headcount increased materially year over year with multiple recent job postings and self-described profitable growth. Long-standing B‑Corp certification and published impact throughput (e.g., assets repurposed, community partners) suggest durable operations aligned to mission.

Investor Backing & Capital Strength: Recent funding led by Andreessen Horowitz and a disclosed Series B provide fresh capital and visible investor confidence. The company links this capital to planned expansion across additional care settings and broader U.S. reach.

Market Expansion: Operating presence across many states, rising claims throughput, and stated plans to grow into home health, long‑term care, and substance use disorder point to ongoing geographic and segment expansion. Company materials cite increasing footprint and scale since its February 2025 launch.

Innovation-Driven Growth: An AI‑driven reimbursement platform reporting high first‑pass claims acceptance and fewer denials indicates product performance that can support scaling. Case examples and platform claims suggest the technology is enabling faster, more accurate payments and broader adoption.

Strong Revenue Growth: Financial results indicate revenue rebounded to roughly $1.0–$1.04 billion in 2025 with continued quarterly momentum, and management guided to about $1.4 billion in 2026—signaling further expansion.

Profitability: The company returned to GAAP profitability in late 2025, reporting positive net income for the year and demonstrating operating leverage as volumes recovered.

Strategic Partnerships: Upstart added new bank and credit‑union partners and emphasized strong retention among private‑credit funding partners, with multi‑year forward‑flow commitments helping support sustained origination volume.

Strong Revenue Growth: Monthly visits are described as rising materially year-over-year in one passage, alongside references to expanding user activity metrics and ramping annual recurring revenue estimates.

Investor Backing & Capital Strength: Funding is described across multiple rounds and investor participation, with capital explicitly tied to scaling product development, operations, and go-to-market capacity.

Innovation-Driven Growth: Product shipping velocity is framed as frequent and sustained, including AI-native workflow features and a high volume of recent updates that signal ongoing iteration.

Investor Backing & Capital Strength: Evidence indicates the company closed a Series B funding round in December 2023 framed as “funding to profitability.” This supports continued scaling and signals confidence from investors.

Strong Revenue Growth: Company materials and coverage describe substantial expansion in revenue and accounts since its 2022 Series A. Feedback suggests the firm has materially increased monthly account volume while serving millions of borrowers.

Diversified Customer Base: The company highlights working with top card issuers, banks, credit unions, fintechs, and debt buyers, and servicing debt at multi‑billion scale. This breadth points to enterprise adoption and larger claim volumes across segments.

Investor Backing & Capital Strength: Available disclosures indicate Marble closed a $15.5M Series A in Oct 2025 led by Costanoa with Town Hall Ventures and Khosla Ventures participating, adding to earlier seed capital. Feedback suggests this funding is earmarked for hiring, product development, and national rollout.

Market Expansion: Company communications and filings indicate recent launches in Ohio and New Jersey alongside an Ohio legal registration, pointing to a widening footprint beyond its New York base. Feedback suggests ongoing school partnership announcements and active hiring align with multi-state go-to-market execution.

Strategic Partnerships: Public materials highlight growing school partnerships and insurer alignment, with care marketed as in-network and inclusive of Medicaid. Feedback suggests this school-embedded, insurance-billed model is gaining traction amid strong policy tailwinds for youth mental health access.

Investor Backing & Capital Strength: A $150 million Series D at around a $3 billion valuation signals strong investor confidence and provides resources to fund expansion. A favorable funding environment in behavioral health further supports access to capital for scaled platforms.

Strong Revenue Growth: Reported approximately $1 billion in annual revenue alongside 7 million visits in 2025 and 10 million cumulative appointments indicate substantial monetized usage. These utilization and revenue figures point to rapid scale-up over recent years.

Strategic Partnerships: Integrations with 125+ health plans and expansion into employer benefits and health system partnerships broaden distribution beyond the original marketplace. This multi-channel buildout reduces reliance on a single route to market and opens additional growth avenues.

Market Expansion: Public materials indicate the network scaled from over 2,500 community sites in 2023 to 6,000+ research sites and 25+ sponsors across 50+ countries by April 2026. This sequential ramp across sites, sponsors, and geographies suggests continued expansion on both sides of the marketplace.

Strategic Partnerships: New and expanding collaborations—such as AbbVie oncology rollouts and integrations with RealTime eClinical Solutions and CRIO—point to growing demand-side traction and data connectivity. These relationships embed the platform into sponsor and site workflows, reinforcing usage and reach.

Innovation-Driven Growth: The company launched AI Site Selection and AI-powered patient pre-screening in 2025, with 2026 case posts highlighting time and cost savings on active studies. This product velocity and real-world application signal ongoing innovation tied to operational outcomes.

Market Expansion: Active hiring across multiple functions, multi‑state therapist directories on the site, and new senior‑care partnerships indicate the company is broadening geographic reach and access channels.

Strategic Partnerships: Being in‑network with Medicare and collaborating with Advanced Nursing & Home Care suggest integration within senior‑care ecosystems that can accelerate referrals and distribution.

Innovation-Driven Growth: An AI‑native operating system with virtual therapy, care navigation, and AI agents points to a technology‑led approach designed to scale services efficiently.